Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

22 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Apresoline Articles

Deerfield ups NitroMed unsolicited takeover offer

19 January 2009

NitroMed to sell BiDil business to JHP

3 November 2008

NAACP attacks lack of BiDil Medicare coverage

5 February 2007

FDA confirms no drugs equivalent to BiDil

15 May 2006

US minority coalition to aid pharma access

11 July 2005

US docs back Rx ethnic/racial group targeting

4 July 2005

NitroMed's BiDil closer to US FDA approval

27 June 2005

US biotech sector tumbles in July as investors react to choppy market conditions

23 August 2004

NitroMed's BiDil achieves Ph III goals

26 July 2004

NitroMed acquires BiDil NDA for CHF therapy

22 September 1999

FDA Clears SB's Carvedilol For CHF

9 June 1997

Medco/Global Pharm agreement for manufacture of Bidil

31 July 1995

AHCPR Guidelines On Heart Failure Management

27 February 1995

BOEH-MANNHEIM TO SELL MEDCO'S BIDIL

22 November 1993

BOOTS' FLOSEQUINAN IN FURTHER TROUBLE?

14 June 1993

Showing 1-15 of 15 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • Is failure to adopt business process management putting the pharma industry at risk?
  • Boehringer Ingelheim gets FDA warning letter on cGMP failures
  • Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
  • Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • Is failure to adopt business process management putting the pharma industry at risk?
  • Boehringer Ingelheim gets FDA warning letter on cGMP failures
  • Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
  • Ignyta acquires Actagene Oncology and entry into cancer personalized medicine

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS